GENFIT (NASDAQ:GNFT) Stock Price Down 3.4% - Here's What Happened

Key Points

• GENFIT S.A. stock price fell by 3.4% during mid-day trading, with shares trading as low as $3.92 before closing at $3.84.
• A new institutional investor, Millennium Management LLC, recently acquired 166,375 shares of GENFIT, representing about 0.33% of the company's total shares.
• GENFIT is actively developing several treatments for metabolic and liver-related diseases, including Elafibranor, which is in Phase III trials for primary biliary cholangitis.

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report) shares were down 3.4% during trading on Thursday . The company traded as low as $3.92 and last traded at $3.84. Approximately 5,946 shares were traded during trading, an increase of 134% from the average daily volume of 2,546 shares. The stock had previously closed at $3.97.

GENFIT Trading Down 0.3%

The company has a 50-day simple moving average of $3.98 and a two-hundred day simple moving average of $3.82. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.08.

Hedge Funds Weigh In On GENFIT

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC bought a new stake in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 22,238 shares of the company's stock, valued at approximately $76,000. Institutional investors and hedge funds own 2.24% of the company's stock.

GENFIT Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.